Navigation Links
Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis

0.05% dose group were not statistically significant.

There were multiple secondary endpoints in this trial. Among these, statistically significant improvements (p less than or equal to 0.05) compared to placebo were demonstrated in the 0.1% dose group for the secondary endpoints of non-nasal symptom score (itchy eyes, watery eyes, and itchy throat/palate) and for total symptom score (TNSS plus non-nasal symptom score).

Based on the results of this trial and previous discussions with the FDA, Inspire intends to initiate a required 6-month nasal toxicology study of epinastine in a single animal species to support longer-term clinical trials. In addition, a meeting with the FDA will be scheduled to discuss the next steps in the clinical program.

In 2006, Inspire acquired certain exclusive rights from Boehringer Ingelheim International GmbH to develop and market epinastine nasal spray in the United States and Canada for the treatment or prevention of rhinitis.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and be
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional is ... and tissue for a wide range of away ... its product lines in healthcare, including hospitals, long-term ... Professional is introducing its healthcare products and solutions ... understands the importance of infection control in the ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... 30, 2014   Acutus Medical, Inc. ... real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping ... or sustain complex cardiac arrhythmias, including atrial fibrillation, announced ... developing its imaging/mapping system as well as bring to ... Acutus Medical to complete work on the AcQMap TM ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of RenalGuard® ... , a peer-reviewed journal of the American Heart Association ... in the September 2011 issue of the publication.  The ...
... A national analysis conducted by Sperling,s BestPlaces and ... Columbus, Ohio, as one of the nation,s Hypertension ... factors and complications. The identification of the Hypertension ... hypertension awareness program called Commit to Control ...
Cached Medicine Technology:REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 2REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 3REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 4Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 2Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 3Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 4
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... 2014 EverStryke , the permanent match ... SurvivalLife.com along with a free book and class all about ... Michaels, prompting an investigative review. , “Joe Marshall of ... survival and preparation niche, and this product is an excellent ... and survival products that Joe offers on his website to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... President of ... the Lyme Disease Association., JACKSON, N.J., Oct. 4 The ... "A Clinical Appraisal,of ,Chronic Lyme Disease.," Eleven of its authors also ... by the,Connecticut Attorney General for the development of those Guidelines.,Although the ...
... to stress the disease,s link to heart disease , , THURSDAY, Oct. ... pretty. , An acclaimed rock musician and record producer, he was ... Fox television,s soon-to-be monster hit American Idol . , Then ... diabetes. , Today, with his disease under control, Jackson wants to ...
... technological know how to patient care were demonstrated by ... , Imperials Rector, Sir Richard Sykes, and Professor of ... Darzi, took the PM on a tour of the ... The Institute is at the forefront of medical innovation, ...
... Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ) ... to Chief Scientific Officer of Delivery. Dr. Costantino,will ... new,drug delivery technologies for peptide and protein therapeutics. ... is retiring,tomorrow, October 5, 2007, as was previously ...
... Oct. 4 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM: TSX-V) ... the American,College of Surgeons 93rd Annual Clinical Congress ... CRH will be focused on recruiting General ... its number of Centers for,Colorectal Health. Commenting ...
... Series, new rules for the first time forced players to ... and coaches had to strategize how pitchers were used more ... 12 and under could throw up to six innings per ... an increase in reported cases of young pitchers experiencing arm ...
Cached Medicine News:Health News:NEJM Owes Patients Responsible Journalism, Says Lyme Disease Association 2Health News:Randy Jackson Takes Aim at Diabetes 2Health News:Randy Jackson Takes Aim at Diabetes 3Health News:Prime Minister views innovative health technology at Imperial College London 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 3Health News:CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress 2Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: